Pamela Wapnick - 05 Mar 2026 Form 4 Insider Report for Metagenomi Therapeutics, Inc. (MGX)

Role: Chief Financial Officer
Signature: /s/ Matthew L. Wein, attorney-in-fact
Issuer symbol: MGX
Transactions as of: 05 Mar 2026
Net transactions value: -$2,530
Form type: 4
Filing time: 09 Mar 2026, 17:16:44 UTC
Previous filing: 08 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Wapnick Pamela	Chief Financial Officer	C/O METAGENOMI THERAPEUTICS, INC., 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE	/s/ Matthew L. Wein, attorney-in-fact	09 Mar 2026	0001995657

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MGX	Common Stock	Sale	$2,530	-1,581	-0.84%	$1.60	187,375	05 Mar 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person.